View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar Laboratóriumi Medicina Intézet Budapest Baross u. 48–52. 1047
  • 2 Diagon Kft. Budapest
Open access

A trombin a véralvadási kaszkád egyik kulcsenzime, amely mind pro-, mind antikoaguláns funkcióval rendelkezik. Központi szerepe folytán a trombin képződése a véralvadási folyamat egyik legfontosabb lépése, amely az úgynevezett trombingenerációs vizsgálattal jellemezhető. A trombingeneráció globális véralvadási teszt, amely átfogó képet ad a haemostasis állapotáról. Karakterisztikáját egyaránt befolyásolják a pro- és az antikoaguláns folyamatok, ezáltal alkalmas a fokozott trombóziskészség és a vérzékenység kimutatására is. Klinikai vizsgálatok igazolják a trombingeneráció fokozódását vénás és artériás trombózishajlam esetében. Segíthet az antikoaguláns terápia monitorozásában, faktorinhibitorokkal történő antikoaguláns kezelés esetében is. A trombingenerációs vizsgálatok eredményei hemofília esetén jól tükrözik a vérzés súlyosságát, és monitorozható a faktorkészítményekkel történő terápia. Információt adhat azokban az esetekben is, amikor a hemofíliás betegnél inhibitorok jelennek meg, és emiatt speciális kezelésre van szükség. A klinikai gyakorlatban történő alkalmazáshoz elengedhetetlen a módszer standardizálása és a klinikai döntéshozatalhoz szükséges küszöbértékek meghatározása. Orv. Hetil., 2014, 155(22), 851–857.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Crawley, J. T., Zanardelli, S., Chion, C. K., et al.: The central role of thrombin in hemostasis. J. Thromb. Haemost., 2007, 5(Suppl. 1), 95–101.

  • Mosesson, M. W.: Fibrinogen and fibrin structure and functions. J. Thromb. Haemost., 2005, 3(8), 1894–1904.

  • Mann, K. G.: Thrombin formation. Chest, 2003, 124(3 Suppl.), 4S–10S.

  • Esmon, C. T.: Molecular events that control the protein C anticoagulant pathway. Thromb. Haemost., 1993, 70(1), 29–35.

  • Coughlin, S. R.: Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost., 2005, 3(8), 1800–1814.

  • Ten Cate, H.: Thrombin generation in clinical conditions. Thromb. Res., 2012, 129(3), 367–370.

  • Bauer, K. A.: Activation markers of coagulation. Baillieres Best Pract. Res. Clin. Haematol., 1999, 12(3), 387–406.

  • Biggs, R., Macfarlane, R. G.: Human blood coagulation and its disorders. Blackwell, Oxford, 1953.

  • Berntorp, E., Salvagno, G. L.: Standardization and clinical utility of thrombin-generation assays. Semin. Thromb. Hemost., 2008, 34(7), 670–682.

  • Loeffen, R., Kleinegris, M. C., Loubele, S. T., et al.: Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method. J. Thromb. Haemost., 2012, 10(12), 2544–2554.

  • Béguin, S., Lindhout, T., Hemker, H. C.: The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb. Haemost., 1989, 61(1), 25–29.

  • Luddington, R., Baglin, T.: Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J. Thromb. Haemost., 2004, 2(11), 1954–1959.

  • De Smedt, E., Hemker, H. C.: Thrombin generation is extremely sensitive to preheating conditions. J. Thromb. Haemost., 2011, 9(1), 233–234.

  • Hemker, H. C., Wielders, S., Kessels, H., et al.: Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb. Haemost., 1993, 70(4), 617–624.

  • Hemker, H. C., Giesen, P. L., Ramjee, M., et al: The thrombogram: Monitoring thrombin generation in platelet rich plasma. Thromb. Haemost., 2000, 83(4), 589–591.

  • Ninivaggi, M., Apitz-Castro, R., Dargaud, Y., et al.: Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin. Chem., 2012, 58(8), 1252–1259.

  • Dargaud, Y., Luddington, R., Gray, E., et al.: Standardisation of thrombin generation test – which reference plasma for TGT? An international multicentre study. Thromb. Res., 2010, 125(4), 353–356.

  • Hron, G., Kollars, M., Binder, B. R., et al.: Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA, 2006, 296(4), 397–402.

  • Eichinger, S., Hron, G., Kollars, M., et al.: Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin. Chem., 2008, 54(12), 2042–2048.

  • Tripodi, A., Legnani, C., Chantarangkul, V., et al.: High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J. Thromb. Haemost., 2008, 6(8), 1327–1333.

  • Tripodi, A., Legnani, C., Lemma, L., et al.: Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. J. Thromb. Thrombolysis, 2010, 30(2), 215–219.

  • Van Hylckama Vlieg, A., Christiansen, S. C., Luddington, R., et al.: Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Brit. J. Haematol., 2007, 138(6), 769–774.

  • Ferroni, P., Martini, F., Portarena, I., et al.: An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. Thromb. Haemost., 2011, 105(5), 931–932.

  • Ferroni, P., Martini, F., Portarena, I., et al.: Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients – a pilot study. Support Care Cancer, 2012, 20(11), 2713–2720.

  • Marchetti, M., Castoldi, E., Spronk, H. M., et al.: Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood, 2008, 112(10), 4061–4068.

  • Panova-Noeva, M., Marchetti, M., Spronk, H. M., et al.: Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am. J. Hematol., 2011, 86(4), 337–342.

  • Trappenburg, M. C., van Schilfgaarde, M., Marchetti, M., et al.: Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica, 2009, 94(7), 911–918.

  • Brocal, I., Marco, P., Lucas, J., et al.: Thrombin generation test in patients under anticoagulant therapy with vitamin K antagonists. Thromb. Haemost., 2009, 101(3), 594–595.

  • Altman, R., Scazziota, A., Herrera, L., et al.: Relationship between thrombin generation and international normalized ratio in patients receiving oral vitamin K antagonist therapy. J. Thromb. Haemost., 2007, 5(7), 1552–1569.

  • Gerotziafas, G. T., Dupont, C., Spyropoulos, A. C., et al.: Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin. Thromb. Haemost., 2009, 102(1), 42–48.

  • Al Dieri, R., Alban, S., Béguin, S., et al.: Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J. Thromb. Haemost., 2004, 2(8), 1395–1401.

  • Gouya, G., Palkovits, S., Kapiotis, S., et al.: Bioactivity of enoxaparin in critically ill patients with normal renal function. Br. J. Clin. Pharmacol., 2012, 74(5), 806–814.

  • Gatt, A., van Veen, J. J., Woolley, A. M., et al.: Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb. Haemost., 2008, 100(2), 350–355.

  • Keltai, M., Keltai, K.: New anticoagulants in the prevention and treatment of venous thromboembolism. [Új antikoagulánsok a vénás thromboembolia megelőzésében.] Orv. Hetil., 2011, 152(25), 983–992. [Hungarian]

  • Graff, J., von Hentig, N., Misselwitz, F., et al.: Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J. Clin. Pharmacol., 2007, 47(11), 1398–1407.

  • Wong, P. C., White, A., Luettgen, J.: Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay. Hosp. Pract., 2013, 41(1), 19–25.

  • Borissoff, J. I., Joosen, I. A. P. G., Versteylen, M. O., et al: Enhanced endogenous thrombin potential is associated with the severity of coronary atherosclerosis. J. Thromb. Haemost., 2011, 9(Suppl. 2), 746.

  • Carcaillon, L., Alhenc-Gelas, M., Bejot, Y., et al.: Increased thrombin generation is associated with acute ischemic stroke but not with coronary heart disease in the elderly. The three-city cohort study. Arterioscler. Thromb. Vasc. Biol., 2011, 31(6), 1445–1451.

  • Faber, C. G., Lodder, J., Kessels, F., et al.: Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients. Pathophysiol. Haemost. Thromb., 2003, 33(1), 52–58.

  • Peyvandi, F., Mannucci, P. M.: Rare coagulation disorders. Thromb. Haemost., 1999, 82(4), 1207–1214.

  • Van den Berg, H. M., De Groot, P. H., Fischer, K.: Phenotypic heterogeneity in severe hemophilia. J. Thromb. Haemost., 2007, 5(Suppl. 1), 151–156.

  • Duchemin, J., Pan-Petesch, B., Arnaud, B., et al.: Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb. Haemost., 2008, 99(4), 767–773.

  • Shima, M., Matsumoto, T., Ogiwara, K.: New assays for monitoring haemophilia treatment. Haemophilia, 2008, 14(Suppl. 3), 83–92.

  • Keularts, I. M., Hamulyak, K., Hemker, H. C., et al.: The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. Thromb. Haemost., 2000, 84(4), 638–642.

  • Váradi, K., Negrier, C., Berntorp, E., et al.: Monitoring the bioavailability of FEIBA with a thrombin generation assay. J. Thromb. Haemost., 2003, 1(11), 2374–2380.

  • Schols, S. E., Lancé, M. D., Feijge, M. A., et al.: Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb. Haemost., 2010, 103(2), 318–328.